News /

CiMaas and Kiadis decided to stop collaborating on the production of Natural Killer Cells

While CiMaas is able to produce the required high numbers of natural killer (NK) cells intended to realise in the collaboration, we decided not to continue. Kiadis has refocused its clinical strategy to a concept of universal donors while CiMaas keeps working on the process of individual donors for each cancer patient where NK cells will be transfused in combination with a bone marrow transplantation.  

News /

CiMaas and the INsTRuCT Consortium receive EU subsidy to train young scientists in developing novel cell therapies

Cell therapy is an active area of immunological research and represents a highly innovative and rapidly expanding sector of the pharmaceutical industry. CiMaas is part of the the INsTRuCT Consortium (www.instruct-h2020.eu) which comprises 15 different European companies or universities from 8 Member States, that answers an unmet need for postdoctoral researchers trained in scientifically excellent research and cell therapy development.

News /

Neuroplast and CiMaas join forces

Neuroplast and CiMaas, developers and producers of regenerative cell therapies, are setting up joint shop at the Brightlands Chemelot Campus in Geleen where they will be sharing a new laboratory and office space. Both companies currently employ around 30 people and expect to experience substantial growth.

News /

CiMaas featured in Brightlands media campaign

The national campaign - to the end of June 2019 - airs radiospots and runs advertisements in several national newspapers to draw attention to the collaboration between the University and Brightlands in developing solutions for important societal issues. CiMaas regenerates the immune system to fight cancer.

News /

CiMaas obtains gene therapy classification from EMA for its’ DC vaccine

Upon a recent application and discussion with EMA, Cimaas received the classification for its' dendritic cell vaccine. EMA/CAT considers that the WT1-DC-Xcite-L1 falls within the definitions of a somatic cell therapy medicinal product and a gene therapy medicinal product and based on that is considered as gene therapy medicinal product as provided in Article 2(5) of Regulation (EC) No 1394/2007.

News /

CiMaas receives ATMP classification from EMA for NK cell product

CiMaas recently applied for a classification for its’ Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma. Upon this request, the European Medicines Agency / Committee for Advanced Therapies considers that product NK-Xpand-MM1 falls within the definition of somatic cell therapy medicinal product, as provided in Article 2 of Regulation (EC) No 1394/2007. This classification marks the first step of the regulatory pathway CiMaas has taken to obtain the manufacturing license to produce Natural Killer cells in its’ planned clinical trial for patients with multiple myeloma.
News /

CiMaas receives second tranche of financing

Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.
This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.
News /

CiMaas starts 2017 with successful first investment

MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V.  invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.